Italy· 044020016
SIVEXTRO*6 cpr rivestite 200 mg
A tedizolid product containing tedizolid, registered in Italy by MERCK SHARP & DOHME BV, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.
Checked against the register on
Informational only — not a medical device.
Where it is registered
Tedizolid is registered in 14 of 19 countries.
Countries holding a registration under ATC J01XX11 (tedizolid), each read from that country’s own register.
- This record: Italy
- 10 of them publish a price we can compare per daily dose
Tedizolid · ATC J01XX11
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of tedizolid costs, country by country.
Normalised to the WHO defined daily dose (0.2 g), so markets compare like for like.
- Italy: $346.95 per daily dose (median across products in the class)
- Public list prices, converted to USD at the rate date shown
Tedizolid · price per daily dose (0.2 g)
USD · FX 28 Sept 2026
- IT Italy$346.95
The record
At a glance
- Active substance
- Tedizolid
- Manufacturer
- MERCK SHARP & DOHME BV
- Country
- Italy (IT)
- ATC code
- J01XX11
- ATC class
- Tedizolid
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Yes
- Last checked
- June 4, 2026
Packs & prices · 1
1 priced- aic044020016SIVEXTRO*6 cpr rivestite 200 mgEUR 1828.47
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
51 interactions on record for tedizolid.
Graded by severity as the source publishes them — 2 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tedizolid · interactions on record
51 records
- 2 severe
- 49 moderate
Most severe, free to view
- OzanimodL04AA38severe
- OzanimodL04AE02severe
- Sodium picosulfateA06AB08moderate
- SulfasalazineA07EC01moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tedizolid in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSIVEXTROMerck Sharp & Dohme B.V., Haarlem
- NetherlandsSivextro 200 mg filmomhulde tablettenMerck Sharp & Dohme B.V.
- FinlandSivextroMerck Sharp & Dohme B.V.
- BelgiumSivextro 200 mgMerck Sharp & Dohme
- SwedenSivextro 200 mg Filmdragerad tablettMerck Sharp & Dohme BV
- Japanテジゾリドリン酸エステルＭＳＤ
- NorwaySivextroMerck Sharp & Dohme B.V. (1)
- PolandSivextroMerck Sharp & Dohme B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Sivextro
- Liechtenstein · Sivextro
- Norway · Sivextro
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of the issuing authority. This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7626ff61-3cd2-4e7d-9588-4649dc369559 GET /v1/drugs/7626ff61-3cd2-4e7d-9588-4649dc369559?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"price": 1828.47,
"source": "aifa",
"currency": "EUR",
"strength": "TEDIZOLID 200MG 6 UNITA' USO ORALE",
"substance": "Tedizolid",
"equivalence_group": "JXX",
"transparency_flag": null
}See everything about tedizolid.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.